{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.45","value":"45.0"},{"groupId":"OG001","spread":"22.45","value":"24.1"},{"groupId":"OG002","spread":"12.22","value":"26.6"},{"groupId":"OG003","spread":"19.47","value":"24.7"},{"groupId":"OG004","spread":"19.58","value":"40.7"},{"groupId":"OG005","spread":"19.40","value":"21.0"},{"groupId":"OG006","spread":"17.88","value":"21.2"},{"groupId":"OG007","spread":"21.15","value":"31.5"},{"groupId":"OG008","spread":"23.37","value":"29.0"},{"groupId":"OG009","spread":"15.89","value":"26.7"},{"groupId":"OG010","spread":"20.15","value":"25.6"},{"groupId":"OG011","spread":"8.88","value":"18.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"DS, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.86","value":"-14.8"},{"groupId":"OG001","spread":"27.50","value":"-8.3"},{"groupId":"OG002","spread":"9.34","value":"10.0"},{"groupId":"OG003","spread":"36.00","value":"-5.6"},{"groupId":"OG004","spread":"26.76","value":"23.3"},{"groupId":"OG005","spread":"19.64","value":"-2.8"},{"groupId":"OG006","spread":"10.39","value":"-8.3"},{"groupId":"OG007","spread":"22.22","value":"5.6"},{"groupId":"OG008","spread":"15.71","value":"5.6"},{"groupId":"OG009","spread":"18.43","value":"-2.8"},{"groupId":"OG010","spread":"20.48","value":"12.5"},{"groupId":"OG011","spread":"13.13","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"DS, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.65","value":"27.5"},{"groupId":"OG001","spread":"18.64","value":"21.0"},{"groupId":"OG002","spread":"11.20","value":"19.9"},{"groupId":"OG003","spread":"13.87","value":"18.8"},{"groupId":"OG004","spread":"13.79","value":"23.6"},{"groupId":"OG005","spread":"6.87","value":"7.7"},{"groupId":"OG006","spread":"9.65","value":"12.7"},{"groupId":"OG007","spread":"9.43","value":"15.1"},{"groupId":"OG008","spread":"6.21","value":"14.9"},{"groupId":"OG009","spread":"14.21","value":"16.7"},{"groupId":"OG010","spread":"13.60","value":"13.9"},{"groupId":"OG011","spread":"8.99","value":"11.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"SET, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.19","value":"-11.4"},{"groupId":"OG001","spread":"15.71","value":"-14.8"},{"groupId":"OG002","spread":"7.86","value":"0.1"},{"groupId":"OG003","spread":"9.07","value":"0.0"},{"groupId":"OG004","spread":"14.60","value":"0.0"},{"groupId":"OG005","spread":"7.86","value":"1.9"},{"groupId":"OG006","spread":"5.00","value":"3.3"},{"groupId":"OG007","spread":"19.38","value":"19.0"},{"groupId":"OG008","spread":"6.81","value":"1.1"},{"groupId":"OG009","spread":"8.74","value":"-2.7"},{"groupId":"OG010","spread":"8.74","value":"5.6"},{"groupId":"OG011","spread":"20.14","value":"6.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"SET, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.57","value":"83.3"},{"groupId":"OG001","spread":"0.00","value":"100.0"},{"groupId":"OG002","spread":"31.62","value":"76.7"},{"groupId":"OG003","spread":"24.22","value":"81.5"},{"groupId":"OG004","spread":"29.59","value":"77.8"},{"groupId":"OG005","spread":"24.22","value":"85.2"},{"groupId":"OG006","spread":"37.87","value":"69.7"},{"groupId":"OG007","spread":"16.67","value":"88.9"},{"groupId":"OG008","spread":"33.33","value":"77.8"},{"groupId":"OG009","spread":"22.50","value":"90.0"},{"groupId":"OG010","spread":"14.05","value":"93.3"},{"groupId":"OG011","spread":"34.50","value":"75.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"BI, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"50.92","value":"-11.1"},{"groupId":"OG001","spread":"23.57","value":"-16.7"},{"groupId":"OG002","spread":"31.91","value":"-8.3"},{"groupId":"OG003","spread":"41.94","value":"8.3"},{"groupId":"OG004","spread":"14.91","value":"6.7"},{"groupId":"OG005","spread":"0.00","value":"0.0"},{"groupId":"OG006","spread":"0.00","value":"0.0"},{"groupId":"OG007","spread":"16.27","value":"-9.5"},{"groupId":"OG008","spread":"0.00","value":"0.0"},{"groupId":"OG009","spread":"16.67","value":"-8.3"},{"groupId":"OG010","spread":"16.67","value":"-8.3"},{"groupId":"OG011","spread":"19.25","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"BI, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.65","value":"58.9"},{"groupId":"OG001","spread":"12.83","value":"48.1"},{"groupId":"OG002","spread":"28.71","value":"58.9"},{"groupId":"OG003","spread":"16.77","value":"72.8"},{"groupId":"OG004","spread":"17.38","value":"65.7"},{"groupId":"OG005","spread":"17.07","value":"67.9"},{"groupId":"OG006","spread":"31.03","value":"55.6"},{"groupId":"OG007","spread":"23.57","value":"59.3"},{"groupId":"OG008","spread":"34.15","value":"58.0"},{"groupId":"OG009","spread":"15.00","value":"62.2"},{"groupId":"OG010","spread":"16.60","value":"63.3"},{"groupId":"OG011","spread":"13.28","value":"66.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"FP, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51.32","value":"-7.4"},{"groupId":"OG001","spread":"39.28","value":"38.9"},{"groupId":"OG002","spread":"19.25","value":"16.7"},{"groupId":"OG003","spread":"13.98","value":"13.9"},{"groupId":"OG004","spread":"21.66","value":"-6.7"},{"groupId":"OG005","spread":"15.71","value":"0.0"},{"groupId":"OG006","spread":"14.77","value":"1.9"},{"groupId":"OG007","spread":"22.87","value":"-3.2"},{"groupId":"OG008","spread":"7.86","value":"-5.6"},{"groupId":"OG009","spread":"31.91","value":"-8.3"},{"groupId":"OG010","spread":"44.79","value":"-2.8"},{"groupId":"OG011","spread":"15.71","value":"22.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"FP, CFB to EoT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"description":"The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The module comprised of 20 questions that addressed four myeloma-specific HRQoL domains: disease symptoms (DS), side effects of treatment (SET), future perspective (FP) and body image (BI). Responses are 1 to 4. Scores were averaged and scales were transformed to 0 to 100 scale. A high score for disease symptoms and side effects of treatment represented a high level of symptomatology or problems, whereas a high score for future perspective and body image represented better outcomes. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 1.9 milligram (mg)/kilogram (kg) dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide (Len) was administered as 25 mg or 10 mg per oral (PO) on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone (Dex) weekly PO/ intravenously (IV) on Days 1, 8, 15 and 22 of each cycle.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg STRETCH + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG001","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG002","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG003","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of every alternate 21-day cycle (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib (Bor) was administered as 1.3 milligrams per square meters (mg/m\\^2) subcutaneously (SC) /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone (Dex) PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG004","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG005","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on cycle 1 day 1 (C1D1) followed by 1.9 mg/kg step-down dose on Day 1 of every alternate 21-day cycles C3 onwards (C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG006","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every alternate 21-day cycles (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG007","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg on Day 1 and 1.25 mg/kg dose on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG008","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG009","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 3.4 mg/kg dose as a 1.7 mg/kg dose on Day 1 and 1.7 mg/kg on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG010","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 3.4 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG011","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex"}],"paramType":"MEAN","populationDescription":"All Treated. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 4.5 years (End of treatment [EoT])","title":"Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score","type":"SECONDARY","unitOfMeasure":"Score on scale"}